genome, genomic revolution, arkg, arkgenome, CRISPR, gene therapy, james bannon, ARK, ARK Investment Management, Innovation, ETF, Active management, thematic, investing, disruptive innovation, investment management

Spell-Checking the Language of Life: CRISPR Gene Editing In Living Animals

Repairing a genetic mutation could eliminate a lifetime of suffering. Until recently, the only option was gene therapy, which many perceive as risky. Recent successes in gene therapy and new advances in gene editing technology may mean doctors and patients will have many options. Researchers have worked for years to devise techniques to surmount the challenges associated with altering a genome safely. The latest of these, CRISPR, has moved beyond the proof-of-concept stage, as MIT researchers have used the technique to reverse a disease in a living organism.

The research, conducted on mice, reversed a mutation that prevents organisms from producing a particular enzyme called FAH. Left untreated, FAH can lead to liver failure. Current treatments include a low-protein diet and various medicines. In contrast, CRISPR could help the 3,000 American sufferers lead entirely normal lives.

The potential impact of CRISPR on the standard of care is obvious: with as little as one treatment many chronic and painful diseases could become curable. If it continues to find success, the 20,000 Americans suffering from hemophilia and 30,000 from Huntington’s disease may not have to face life with an incurable disease. Aggregate ongoing annual treatment costs for these two diseases runs into the billions of dollars -approximately $7.1 billion for Huntington’s1 and $16 billion for hemophilia2. Replacing that ongoing expense with a one-time regimen would result in profound economic and quality of life benefits. It would also put existing franchises, which address these diseases [Baxter International BAX , Biogen Idec BIIB and Prana Biotechnology PRAN] at risk.

While CRISPR is an exciting new technology, it is several years from clinical use and is only one of many shots that may hit the target. Bluebird Bio BLUE , Celladon CLDN and Uniqure QURE all have raised money in the public markets based on the potential viability of their gene therapies. Could it be only a matter of time before congenital diseases become a curse of the past?


  1. Assuming 5 in every 100,000 people have Huntingtons and an annual care cost (on average across all stages) of 20000:
  2. There are 400,000 people worldwide living with hemophilia, at a cost of $40,000 per year then on aggregate we have a spend of $16 billion.

The information provided is for informational purposes only. It does not constitute any form of advice or recommendation to buy or sell any securities mentioned. It is intended only to provide observations and views of the author(s) at the time of writing, both of which are subject to change at any time without prior notice. Certain of the statements contained herein are statements of future expectations and other forward-looking statements that are based on ARK's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Past performance is no guarantee of future results. Equities may decline in value due to both real and perceived general market, economic, and industry conditions. For a list of all purchases and sales made by ARK for client accounts during the past year that could be considered by the SEC as recommendations, click here. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. For full disclosures, click here.